Summit Therapeutics plc (SMMT): Price and Financial Metrics


Summit Therapeutics plc (SMMT): $5.05

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SMMT POWR Grades


  • SMMT scores best on the Sentiment dimension, with a Sentiment rank ahead of 90.61% of US stocks.
  • The strongest trend for SMMT is in Momentum, which has been heading down over the past 52 weeks.
  • SMMT ranks lowest in Momentum; there it ranks in the 4th percentile.

SMMT Stock Summary

  • SMMT's price/sales ratio is 283.11; that's higher than the P/S ratio of 98.45% of US stocks.
  • With a year-over-year growth in debt of 235.22%, Summit Therapeutics Inc's debt growth rate surpasses 95.83% of about US stocks.
  • As for revenue growth, note that SMMT's revenue has grown 183.41% over the past 12 months; that beats the revenue growth of 95.83% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Summit Therapeutics Inc, a group of peers worth examining would be NRIX, PTGX, SYRS, IDYA, and ORMP.
  • Visit SMMT's SEC page to see the company's official filings. To visit the company's web site, go to www.summitplc.com.

SMMT Valuation Summary

  • SMMT's price/sales ratio is 1262; this is 11018.94% higher than that of the median Healthcare stock.
  • Over the past 79 months, SMMT's EV/EBIT ratio has gone down 2.6.
  • SMMT's price/sales ratio has moved NA NA over the prior 79 months.

Below are key valuation metrics over time for SMMT.

Stock Date P/S P/B P/E EV/EBIT
SMMT 2021-08-31 1262.0 6.5 -10.6 -9.2
SMMT 2021-08-30 1271.5 6.5 -10.7 -9.3
SMMT 2021-08-27 1309.4 6.7 -11.0 -9.6
SMMT 2021-08-26 1281.0 6.6 -10.8 -9.4
SMMT 2021-08-25 1262.0 6.5 -10.6 -9.2
SMMT 2021-08-24 1282.6 6.6 -10.8 -9.4

SMMT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SMMT has a Quality Grade of D, ranking ahead of 7.27% of graded US stocks.
  • SMMT's asset turnover comes in at 0.006 -- ranking 406th of 682 Pharmaceutical Products stocks.
  • EDIT, SAGE, and SVRA are the stocks whose asset turnover ratios are most correlated with SMMT.

The table below shows SMMT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.006 1 -10.188
2020-12-31 0.009 1 -12.994
2019-10-31 -0.197 1 -4.153
2019-07-31 -0.198 1 -4.482
2019-04-30 0.605 1 1.189
2019-01-31 0.604 1 0.877

SMMT Price Target

For more insight on analysts targets of SMMT, see our SMMT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.50 Average Broker Recommendation 1.5 (Moderate Buy)

SMMT Stock Price Chart Interactive Chart >

Price chart for SMMT

SMMT Price/Volume Stats

Current price $5.05 52-week high $12.30
Prev. close $5.05 52-week low $4.38
Day low $4.90 Volume 88,337
Day high $5.12 Avg. volume 202,087
50-day MA $5.24 Dividend yield N/A
200-day MA $6.43 Market Cap 493.46M

Summit Therapeutics plc (SMMT) Company Bio


Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company was founded in 2003 and is based in Abingdon, England.


SMMT Latest News Stream


Event/Time News Detail
Loading, please wait...

SMMT Latest Social Stream


Loading social stream, please wait...

View Full SMMT Social Stream

Latest SMMT News From Around the Web

Below are the latest news stories about Summit Therapeutics Inc that investors may wish to consider to help them evaluate SMMT as an investment opportunity.

Summit Therapeutics (NASDAQ:SMMT) Announces Quarterly Earnings Results

Summit Therapeutics (NASDAQ:SMMT) announced its earnings results on Monday. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.09, MarketWatch Earnings reports. Summit Therapeutics had a negative return on equity of 96.34% and a negative net margin of 350.72%. SMMT stock opened at $5.41 on Thursday. []

Dakota Financial News | November 18, 2021

Summit Therapeutics (NASDAQ:SMMT) Shares Cross Below 50-Day Moving Average of $5.48

Summit Therapeutics Inc. (NASDAQ:SMMT) shares passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $5.48 and traded as low as $5.15. Summit Therapeutics shares last traded at $5.20, with a volume of 84,598 shares traded. Separately, Zacks Investment Research upgraded Summit Therapeutics from a strong []

Transcript Daily | November 17, 2021

Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2021

Cambridge, Massachusetts, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the third quarter and nine months ended September 30, 2021. Note: A glossary of terms is included at the end of this document in order to allow for the ease of understanding of terms or concepts used throughout this release. Financial Highlights Aggregate cash, accounts rec

Yahoo | November 15, 2021

Analysts Expect Summit Therapeutics Inc. (NASDAQ:SMMT) Will Post Earnings of -$0.29 Per Share

Analysts expect that Summit Therapeutics Inc. (NASDAQ:SMMT) will post ($0.29) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Summit Therapeutics earnings. Summit Therapeutics posted earnings of ($0.25) per share during the same quarter last year, which would indicate a negative year over year growth []

Dakota Financial News | November 5, 2021

Summit Therapeutics Bolsters Its Board of Directors with Seasoned Regulatory & Clinical Research Executive Dr. Urte Gayko

Cambridge, Massachusetts, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Dr. Urte Gayko, PhD, has been appointed to our Board of Directors, effective immediately. Dr. Gayko is currently the Senior Vice President of Drug Development & Regulatory Affairs at Nektar Therapeutics. Dr. Gayko previously served as the Global Head of Regulatory Affairs and Pharmacovigilance at Pharmacyclics, Inc., and has over 20 years of experience in areas encompassing re

Yahoo | November 3, 2021

Read More 'SMMT' Stories Here

SMMT Price Returns

1-mo -2.13%
3-mo -30.63%
6-mo -35.01%
1-year 12.22%
3-year 288.46%
5-year -50.20%
YTD 7.45%
2020 193.75%
2019 39.13%
2018 -89.62%
2017 29.44%
2016 -25.57%

Continue Researching SMMT

Here are a few links from around the web to help you further your research on Summit Therapeutics plc's stock as an investment opportunity:

Summit Therapeutics plc (SMMT) Stock Price | Nasdaq
Summit Therapeutics plc (SMMT) Stock Quote, History and News - Yahoo Finance
Summit Therapeutics plc (SMMT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8039 seconds.